A randomised controlled trial of the monoaminergic stabiliser (−)-OSU6162 in treatment of myalgic encephalomyelitis/chronic fatigue syndrome

Nilsson, Mikael; Zachrisson, Olof; Gottfries, C. G.; Matousek, Michael; Peilot, Birgitta; Forsmark, Sara; Schuit, Robert C.; Carlsson, Maria; Kloberg, Angelica; Carlsson, Arvid

doi:10.1017/neu.2017.35

Cited by 12 publications

(25 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(−)‐OSU6162 has been observed to relieve mental fatigue in post stroke and head trauma patients . In this and other previous clinical studies carried out in Sweden, (−)‐OSU6162 was well tolerated with only mild to moderate adverse events …”

Section: Introductionsupporting

confidence: 67%

Open study with (−)-OSU6162 in multiple sclerosis-related fatigue

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 67%

Open study with (−)-OSU6162 in multiple sclerosis-related fatigue

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, we decided to use as reference papers to evaluate common drug-based ME/CFS therapies the recent reviews by Collatz et al, and Smith et al, [97,98]. Additional bibliography supporting the use of polypharmacy in ME/CFS was also included [48,97,[99][100][101][102][103][104][105][106][107]. Similar to what has been described in the previous section 3.3.1. a documented summary of drugs commonly prescribed to ME/CFS patients that could impact miRNA screenings is shown in Table 4 together with active principles and IUPAC names.…”

Section: Polypharmacy In Me/cfsmentioning

confidence: 99%

“…Collatz A et al, 2016 [97] Proliferation inductor from B cells Although possibly not complete, Tables 3 and 4 include the most representative compounds to treat FM and ME/CFS according to the consulted authors [44,48,[76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][99][100][101][102][103][104][105][106][107]. Unexpectedly, a single IUPAC overlap, corresponding to the Selective Serotonin Reuptake Inhibitor (SSRI) Fluoxetine, was found for drugs commonly prescribed for FM and ME/CFS (in bold in Tables 3 &4); indicating little prescription overlap at the IUPAC name level despite both groups of patients presenting common symptomatology.…”

Section: Othersmentioning

confidence: 99%

Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking back on Treatments

Almenar-Pérez

Sánchez-Fito

Ovejero

et al. 2019

Preprint

View full text Add to dashboard Cite

Fibromyalgia (FM) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are diseases of unknown etiology presenting complex and often overlapping symptomatology. Despite promising advances on the study of miRNomes of these diseases, no validated molecular diagnostic biomarker yet exists. Since FM and ME/CFS patient treatments commonly include polypharmacy it is of concern that biomarker miRNAs are masked by drug interactions. Aiming at discriminating between drug-effects and true disease-associated differential miRNA expression, we evaluated the potential impact of commonly prescribed drugs on disease miRNomes, as reported by the literature. By using the web search tools SM2miR, Pharmaco-miR and repoDB, we found a list of commonly prescribed drugs that impact on FM and ME/CFS miRNomes and therefore could be interfering in the process of biomarker discovery. On another end, disease-associated miRNomes may incline patient´s response to treatment and toxicity. Here, we explored treatments for diseases in general that could be affected by FM and ME/CFS miRNomes finding a long list of them, including treatments for lymphoma, a type of cancer affecting ME/CFS patients at a higher rate than healthy population. We conclude that FM and ME/CFS miRNomes could help refine pharmacogenomic/pharmacoepigenomic analysis to elevate future personalized medicine and precision medicine programs in the clinic.

show abstract

“…In 1945, Carlsson married Ulla‐Lisa Christoffersson, and together they had 5 children—three boys and two girls; in their adult life, Maria and Lena became his collaborators. Together with his daughters, he developed the monoaminergic stabilizer (−)‐OSU6162, which is undergoing clinical trials for a variety of neurologic conditions including mental fatigue after stroke and traumatic brain injury myalgic encephalomyelitis/chronic fatigue syndrome …”

mentioning

confidence: 99%

“…Together with his daughters, he developed the monoaminergic stabilizer (−)-OSU6162, which is undergoing clinical trials for a variety of neurologic conditions including mental fatigue after stroke and traumatic brain injury myalgic encephalomyelitis/chronic fatigue syndrome. 6 Based on pridopidine, a dopamine stabilizer and a promising drug candidate for Chorea Huntington, Carlsson established a biotech company, Carlsson Research AB, which subsequently was taken over by the Danish company NeuroSearch A/S that has conducted several clinical trials on pridopidine reaching phase III. 7 Carlsson's active career spanned more than 70 years, and his most recent paper was published in June this year!.…”

mentioning

confidence: 99%